Skip to main content
Top
Published in: Clinical Pharmacokinetics 8/2006

01-08-2006 | Leading Article

Chronopharmacokinetics of Ciclosporin and Tacrolimus

Authors: Prof. Massimo Baraldo, Mario Furlanut

Published in: Clinical Pharmacokinetics | Issue 8/2006

Login to get access

Abstract

The correct use of immunosuppressive drugs has a considerable influence on the prognosis of patients with organ transplants. The appropriate utilisation of the drugs involves the administration of an adequate dosage to reach the blood concentrations that will suppress the alloimmune response, while avoiding secondary toxicities. However, transplanted patients exhibit heterogeneous immunological responses and high inter- and intraindividual pharmacokinetic variabilities. One cause of these variabilities that is rarely considered is circadian rhythms. In vitro and in vivo experiments have clearly demonstrated that all organisms are highly organised according to an internal biological clock that influences various physiological functions. Considering that the absorption, distribution, metabolism and elimination of drugs is influenced by the physiological functions of the body, it is not surprising that the pharmacokinetic, and consequently the pharmacodynamic, profiles of drugs can be influenced by circadian rhythms.
Ciclosporin, a mainstay immunosuppressive drug used following organ transplantation, displays minimum blood concentration (Cmin), maximum blood concentration (Cmax) and area under the blood concentration-time curve (AUC) in the morning that are generally higher than the corresponding parameters in the evening. These observations are supported by the ciclosporin total body clearance and elimination half-life in the morning, which are, on average, higher and shorter, respectively, than those in the evening. In addition, the disposition of tacrolimus is determined by the time of administration. The tacrolimus Cmax and AUC after the morning dose are significantly higher than those after the evening dose.
Finally, the results reported in this review suggest considering more carefully the chronopharmacokinetics of tacrolimus and ciclosporin in order to obtain better results with fewer adverse effects. Significantly, the morning appears to be the best time for therapeutic monitoring using the Cmin, Cmax, concentration at 2 hours after dosing and AUC to modify dosages of tacrolimus and ciclosporin. Less certain are any conclusions about whether, in order to obtain better immunosuppressive control, higher doses must be administered when these drugs are given in the evening to compensate for the higher levels of interleukin-2.
Literature
1.
go back to reference Krensky AM, Strom TB, Bluestone JA. Immunomodulators: immunosuppressive agents, tolerogens and immunostimulants. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1463–84 Krensky AM, Strom TB, Bluestone JA. Immunomodulators: immunosuppressive agents, tolerogens and immunostimulants. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1463–84
2.
go back to reference Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation: how much of the promise has been realized? Nat Med 2005; 11: 605–13PubMedCrossRef Lechler RI, Sykes M, Thomson AW, et al. Organ transplantation: how much of the promise has been realized? Nat Med 2005; 11: 605–13PubMedCrossRef
3.
go back to reference Del Tacca M. Prospects for personalized immunosuppression: pharmacologic tools: a review. Transplant Proc 2004; 36: 687–9PubMedCrossRef Del Tacca M. Prospects for personalized immunosuppression: pharmacologic tools: a review. Transplant Proc 2004; 36: 687–9PubMedCrossRef
4.
go back to reference Johnston A, Holt DW. Immunosuppressant drugs: the role of therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52: 61S–73SPubMedCrossRef Johnston A, Holt DW. Immunosuppressant drugs: the role of therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52: 61S–73SPubMedCrossRef
5.
go back to reference Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7: 401–20PubMedCrossRef Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7: 401–20PubMedCrossRef
6.
go back to reference Lemmer B, Bruguerolle B. Chronopharmacokinetics: are they clinically relevant? Clin Pharmacokinet 1994; 26: 419–27PubMedCrossRef Lemmer B, Bruguerolle B. Chronopharmacokinetics: are they clinically relevant? Clin Pharmacokinet 1994; 26: 419–27PubMedCrossRef
7.
go back to reference Lemmer B. The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res 1996; 33: 107–15PubMedCrossRef Lemmer B. The clinical relevance of chronopharmacology in therapeutics. Pharmacol Res 1996; 33: 107–15PubMedCrossRef
8.
9.
go back to reference Liu C, Reppert SM. GABA synchronizes clock cells within the suprachiasmatic circadian clock. Neuron 2000; 25: 123–8PubMedCrossRef Liu C, Reppert SM. GABA synchronizes clock cells within the suprachiasmatic circadian clock. Neuron 2000; 25: 123–8PubMedCrossRef
10.
go back to reference Hasting MH, Reddy AB, Mayhood ES. A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003; 4: 649–61CrossRef Hasting MH, Reddy AB, Mayhood ES. A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003; 4: 649–61CrossRef
11.
go back to reference Antoch MP, Song E, Chang AM, et al. Functional identification of the mouse circadian clock gene by transgenic BAC rescue. Cell 1997; 89: 655–67PubMedCrossRef Antoch MP, Song E, Chang AM, et al. Functional identification of the mouse circadian clock gene by transgenic BAC rescue. Cell 1997; 89: 655–67PubMedCrossRef
13.
go back to reference Arjona A, Sarkar DK. Circadian oscillations of clock genes, cytolytic factors and cytokines in rat NK cells. J Immunol 2005; 174: 7618–24PubMed Arjona A, Sarkar DK. Circadian oscillations of clock genes, cytolytic factors and cytokines in rat NK cells. J Immunol 2005; 174: 7618–24PubMed
14.
go back to reference Ishida H, Yamashita C, Kuruta Y, et al. Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J Biochem 2000; 127: 57–64PubMedCrossRef Ishida H, Yamashita C, Kuruta Y, et al. Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J Biochem 2000; 127: 57–64PubMedCrossRef
15.
go back to reference Cannon CP. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol 1997; 79: 253–8PubMedCrossRef Cannon CP. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol 1997; 79: 253–8PubMedCrossRef
16.
go back to reference Casetta I, Granieri E, Portaluppi F, et al. Circadian variability in hemorrhagic stroke. JAMA 2002; 287: 1266–7PubMedCrossRef Casetta I, Granieri E, Portaluppi F, et al. Circadian variability in hemorrhagic stroke. JAMA 2002; 287: 1266–7PubMedCrossRef
17.
go back to reference Manfredini R, Poraluppi F, Zamboni P, et al. Circadian variation in spontaneous rupture of abdominal aorta. Lancet 1999; 353: 643–4PubMedCrossRef Manfredini R, Poraluppi F, Zamboni P, et al. Circadian variation in spontaneous rupture of abdominal aorta. Lancet 1999; 353: 643–4PubMedCrossRef
18.
go back to reference Grem JL, Lorrin KY, Venzon DJ, et al. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 1997; 40: 117–25PubMedCrossRef Grem JL, Lorrin KY, Venzon DJ, et al. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 1997; 40: 117–25PubMedCrossRef
19.
20.
go back to reference Born J, Lange TJ, Hansen K, et al. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997; 158: 4454–64PubMed Born J, Lange TJ, Hansen K, et al. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997; 158: 4454–64PubMed
21.
go back to reference Haus E, Lakatua DJ, Swoyer J, et al. Chronobiology in hematology and immunology. Am J Anat 1983; 168(4): 467–517PubMedCrossRef Haus E, Lakatua DJ, Swoyer J, et al. Chronobiology in hematology and immunology. Am J Anat 1983; 168(4): 467–517PubMedCrossRef
22.
go back to reference Levi F, Halberg F. Circaseptan (about-7-day) dioperiodicity - spontaneous and reactive - and the search for pacemakers. Ric Clin Lab 1982; 12: 323–70PubMed Levi F, Halberg F. Circaseptan (about-7-day) dioperiodicity - spontaneous and reactive - and the search for pacemakers. Ric Clin Lab 1982; 12: 323–70PubMed
23.
go back to reference De Vecchi A. Circaseptan rhythmic aspects of rejection in treated patients with kidney transplant. In: Walker CA, Winget CM, Soliman KFA, editors. Chronopharmacology and chemotherapeutics, Tallhassee (FL): A&M University Foundation, 1981: 339–53 De Vecchi A. Circaseptan rhythmic aspects of rejection in treated patients with kidney transplant. In: Walker CA, Winget CM, Soliman KFA, editors. Chronopharmacology and chemotherapeutics, Tallhassee (FL): A&M University Foundation, 1981: 339–53
24.
go back to reference Liu T, Cavallini M, Halberg F, et al. More of the need for circadian, circaseptan, and circannual optimization of cyclosporine therapy. Experientia 1986; 42: 20–2PubMedCrossRef Liu T, Cavallini M, Halberg F, et al. More of the need for circadian, circaseptan, and circannual optimization of cyclosporine therapy. Experientia 1986; 42: 20–2PubMedCrossRef
25.
go back to reference Bowers LD, Canafax J, Singh J, et al. Studies of cyclosporine blood levels: analysis, clinical utility, pharmacokinetics, metabolites, and chronopharmacokinetics. Transplant Proc 1986; 18: 137–43PubMed Bowers LD, Canafax J, Singh J, et al. Studies of cyclosporine blood levels: analysis, clinical utility, pharmacokinetics, metabolites, and chronopharmacokinetics. Transplant Proc 1986; 18: 137–43PubMed
26.
go back to reference Sabatè I, Griñó JM, Castelao AM, et al. Diurnal variations of cyclosporine and metabolites in renal transplant patients. Transplant Proc 1990; 22: 1700–1PubMed Sabatè I, Griñó JM, Castelao AM, et al. Diurnal variations of cyclosporine and metabolites in renal transplant patients. Transplant Proc 1990; 22: 1700–1PubMed
27.
go back to reference Ohlman S, Lindholm A, Hagglund H, et al. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44: 265–9PubMedCrossRef Ohlman S, Lindholm A, Hagglund H, et al. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993; 44: 265–9PubMedCrossRef
28.
go back to reference Milanian I, Ghods AJ, Mahmoudian M, et al. Study of circadian variation of cyclosporine pharmacokinetics. Transplant Proc 1997; 29: 2930–1PubMedCrossRef Milanian I, Ghods AJ, Mahmoudian M, et al. Study of circadian variation of cyclosporine pharmacokinetics. Transplant Proc 1997; 29: 2930–1PubMedCrossRef
29.
go back to reference Iwahori T, Tacheuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc 2005; 37: 1739–40PubMedCrossRef Iwahori T, Tacheuchi H, Matsuno N, et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc 2005; 37: 1739–40PubMedCrossRef
30.
go back to reference Baraldo M, Risaliti A, Bresadola F, et al. Circadian variations in cyclosporine C2 concentrations during the first weeks after liver transplantation. Transplant Proc 2003; 35: 1449–51PubMedCrossRef Baraldo M, Risaliti A, Bresadola F, et al. Circadian variations in cyclosporine C2 concentrations during the first weeks after liver transplantation. Transplant Proc 2003; 35: 1449–51PubMedCrossRef
31.
go back to reference Châteauvert N, Côté H. Circadian variations in the pharmacokinetics of a new microemulsion formulation of cyclosporine in cardiac transplant recipients. Pharmacother 1998; 18: 364–70 Châteauvert N, Côté H. Circadian variations in the pharmacokinetics of a new microemulsion formulation of cyclosporine in cardiac transplant recipients. Pharmacother 1998; 18: 364–70
32.
go back to reference Canafax DM, Cipolle WJM, Hrushesky WJ, et al. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 1988; 20: 471–7PubMed Canafax DM, Cipolle WJM, Hrushesky WJ, et al. The chronopharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 1988; 20: 471–7PubMed
33.
go back to reference Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplant 1996; 62: 1190–2CrossRef Min DI, Chen HY, Fabrega A, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplant 1996; 62: 1190–2CrossRef
34.
go back to reference Min DI, Chen HY, Lee MK, et al. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacother 1997; 17: 457–63 Min DI, Chen HY, Lee MK, et al. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. Pharmacother 1997; 17: 457–63
35.
go back to reference Satoh S, Tada H, Tachiki Y, et al. Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. Int J Urol 2001; 8: 353–8PubMedCrossRef Satoh S, Tada H, Tachiki Y, et al. Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. Int J Urol 2001; 8: 353–8PubMedCrossRef
36.
go back to reference Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859–65PubMedCrossRef Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859–65PubMedCrossRef
37.
go back to reference Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002; 19: 177–89PubMedCrossRef Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002; 19: 177–89PubMedCrossRef
38.
go back to reference Harris BE, Song R, He YJ, et al. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 1998; 37: 4759–62CrossRef Harris BE, Song R, He YJ, et al. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 1998; 37: 4759–62CrossRef
39.
go back to reference Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201PubMed Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201PubMed
40.
go back to reference Levi FA, Zidani R, Vannetzel JL, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608–17PubMedCrossRef Levi FA, Zidani R, Vannetzel JL, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608–17PubMedCrossRef
41.
go back to reference Canal P, Squall A, de Forni M, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991; 40: 287–91PubMedCrossRef Canal P, Squall A, de Forni M, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991; 40: 287–91PubMedCrossRef
42.
go back to reference Koren G, Ferrazzini GM, Sohl H, et al. Chronopharmacology of methotrexate pharmacokinetics in childhood leukaemia. Chronobiol Int 1992; 9: 434–8PubMedCrossRef Koren G, Ferrazzini GM, Sohl H, et al. Chronopharmacology of methotrexate pharmacokinetics in childhood leukaemia. Chronobiol Int 1992; 9: 434–8PubMedCrossRef
43.
go back to reference Kelly JG, O’Malley K. Clinical pharmacokinetics of calcium antagonists: an update. Clin Pharmacokinet 1992; 22: 416–33PubMedCrossRef Kelly JG, O’Malley K. Clinical pharmacokinetics of calcium antagonists: an update. Clin Pharmacokinet 1992; 22: 416–33PubMedCrossRef
44.
go back to reference Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int 1991; 8: 485–94PubMedCrossRef Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int 1991; 8: 485–94PubMedCrossRef
45.
go back to reference Gries JM, Benowitz NL, Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 1996; 60: 385–95PubMedCrossRef Gries JM, Benowitz NL, Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 1996; 60: 385–95PubMedCrossRef
46.
go back to reference Benowitz NL, Chan K, Denaro CP. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin Pharmacol Ther 1991; 50: 286–93PubMedCrossRef Benowitz NL, Chan K, Denaro CP. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin Pharmacol Ther 1991; 50: 286–93PubMedCrossRef
47.
go back to reference Ohdo S, Nakano S, Ogawa N. Chronopharmacokinetics of valproic acid following constant-rate administration in mice. Chronobiol Int 1991; 8: 35–43PubMedCrossRef Ohdo S, Nakano S, Ogawa N. Chronopharmacokinetics of valproic acid following constant-rate administration in mice. Chronobiol Int 1991; 8: 35–43PubMedCrossRef
48.
go back to reference Furlanut M, Benetello P, Mayellaro F, et al. Possible circadian rhythm of diphenylhydantoin metabolism in epileptic patients. Riv Farmacol Ter 1978; 9: 259–66 Furlanut M, Benetello P, Mayellaro F, et al. Possible circadian rhythm of diphenylhydantoin metabolism in epileptic patients. Riv Farmacol Ter 1978; 9: 259–66
49.
go back to reference Labreque G, Belanger PM. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 1991; 52: 95–107CrossRef Labreque G, Belanger PM. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 1991; 52: 95–107CrossRef
50.
go back to reference Feuers RJ, Scheving LE. Chronobiology of hepatic enzymes. Ann Rev Chronopharmacol 1988; 4: 209–54 Feuers RJ, Scheving LE. Chronobiology of hepatic enzymes. Ann Rev Chronopharmacol 1988; 4: 209–54
51.
52.
go back to reference Halloran PF, Helms MH, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplant 1999; 68: 1356–61CrossRef Halloran PF, Helms MH, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplant 1999; 68: 1356–61CrossRef
53.
go back to reference Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001; 61: 1957–2016PubMedCrossRef Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001; 61: 1957–2016PubMedCrossRef
54.
go back to reference Oellerich M, Armstrong VW, Kahan B, et al. Lake Louis Consensus Conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642–54PubMedCrossRef Oellerich M, Armstrong VW, Kahan B, et al. Lake Louis Consensus Conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642–54PubMedCrossRef
55.
go back to reference Nashan B, Bock A, Bosmans JL, et al. Use of neoral C monitoring: a European consensus. Transplant Int 2005; 18: 768–78CrossRef Nashan B, Bock A, Bosmans JL, et al. Use of neoral C monitoring: a European consensus. Transplant Int 2005; 18: 768–78CrossRef
56.
go back to reference Friman S, Backman L. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet 1996; 30: 181–93PubMedCrossRef Friman S, Backman L. A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet 1996; 30: 181–93PubMedCrossRef
57.
go back to reference Bowers LD, Rabatin JT. Circadian pharmacodynamics of cyclosporine in rats and man. In: Reinberg A, Smolensky M, Labrecque G, editors. Annual review of chronopharmacology. Vol. 3. New York: Pergamon Press, 1986: 219–22 Bowers LD, Rabatin JT. Circadian pharmacodynamics of cyclosporine in rats and man. In: Reinberg A, Smolensky M, Labrecque G, editors. Annual review of chronopharmacology. Vol. 3. New York: Pergamon Press, 1986: 219–22
58.
go back to reference Malmary MF, Kabbaj K, Labat C, et al. Chronopharmacokinetics of cyclosporine A in the Wistar rat following oral administration. Eur J Drug Met Pharmacokinet 1992; 17: 135–44CrossRef Malmary MF, Kabbaj K, Labat C, et al. Chronopharmacokinetics of cyclosporine A in the Wistar rat following oral administration. Eur J Drug Met Pharmacokinet 1992; 17: 135–44CrossRef
59.
go back to reference Tredger JM, Chhabra RS. Circadian variations in microsomal drug-metabolizing enzyme activities in rat and rabbit tissue. Xenobiotica 1977; 7: 481–9PubMedCrossRef Tredger JM, Chhabra RS. Circadian variations in microsomal drug-metabolizing enzyme activities in rat and rabbit tissue. Xenobiotica 1977; 7: 481–9PubMedCrossRef
60.
go back to reference Venkataramanan R, Yang S, Burckart GJ, et al. Diurnal variation in cyclosporine kinetics. Ther Drug Monit 1986; 8: 380–1PubMedCrossRef Venkataramanan R, Yang S, Burckart GJ, et al. Diurnal variation in cyclosporine kinetics. Ther Drug Monit 1986; 8: 380–1PubMedCrossRef
61.
go back to reference Heifets M, Cooney GF, Shaw LM, et al. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplant 1995; 60: 1615–7 Heifets M, Cooney GF, Shaw LM, et al. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplant 1995; 60: 1615–7
62.
go back to reference Gupta SK, Southam MA, Hwang SS, et al. Evaluation of diurnal variation in fentanyl clearance. J Clin Pharmacol 1995; 35: 159–62PubMed Gupta SK, Southam MA, Hwang SS, et al. Evaluation of diurnal variation in fentanyl clearance. J Clin Pharmacol 1995; 35: 159–62PubMed
63.
go back to reference Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676–9PubMed Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676–9PubMed
64.
go back to reference Klotz U, Reimann IW. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet 1984; 9: 469–74PubMedCrossRef Klotz U, Reimann IW. Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet 1984; 9: 469–74PubMedCrossRef
65.
go back to reference Queneau P, Decousus H, Ollagnier M, et al. Chronokinetics of ketoprofen administered orally and by continuous venous infusion. Rev Rhum Mal Osteoartic 1985; 52: 403–8PubMed Queneau P, Decousus H, Ollagnier M, et al. Chronokinetics of ketoprofen administered orally and by continuous venous infusion. Rev Rhum Mal Osteoartic 1985; 52: 403–8PubMed
66.
go back to reference Decousus H, Ollagnier M, Cherrah Y, et al. Chronokinetics of ketoprofen infused intravenously at a constant rate. Annu Rev Chronopharmacol 1986; 3: 312–4 Decousus H, Ollagnier M, Cherrah Y, et al. Chronokinetics of ketoprofen infused intravenously at a constant rate. Annu Rev Chronopharmacol 1986; 3: 312–4
67.
go back to reference Bruguerolle B, Dupont M, Lebre P, et al. Bupivacaine chronokinetics in man after a peridural constant rate infusion. Annu Rev Chronopharmacol 1988; 5: 223–6 Bruguerolle B, Dupont M, Lebre P, et al. Bupivacaine chronokinetics in man after a peridural constant rate infusion. Annu Rev Chronopharmacol 1988; 5: 223–6
68.
go back to reference Sanders SW, Bishop AL, Moore JG, et al. Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. Chronobiol Intern 1991; 8: 267–76CrossRef Sanders SW, Bishop AL, Moore JG, et al. Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions. Chronobiol Intern 1991; 8: 267–76CrossRef
69.
go back to reference Philip-Joet F, Bruguerolle B, Lagir F, et al. Effects of a constant dose rate of terbutaline on circadian peak expiratory flow, heart rate and systolic arterial pressure in patients with asthma exacerbation. Respiration 1992; 59: 197–200PubMedCrossRef Philip-Joet F, Bruguerolle B, Lagir F, et al. Effects of a constant dose rate of terbutaline on circadian peak expiratory flow, heart rate and systolic arterial pressure in patients with asthma exacerbation. Respiration 1992; 59: 197–200PubMedCrossRef
70.
go back to reference Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15: 279–90PubMedCrossRef Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15: 279–90PubMedCrossRef
71.
go back to reference Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247–97PubMedCrossRef Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247–97PubMedCrossRef
72.
go back to reference Fujimura A, Shiga T, Ohashi K, et al. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. Jpn J Pharmacol 1993; 61: 137–9PubMedCrossRef Fujimura A, Shiga T, Ohashi K, et al. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. Jpn J Pharmacol 1993; 61: 137–9PubMedCrossRef
73.
go back to reference Fujimura A, Ebihara A. Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK506). Life Sci 1994; 55: 485–90PubMedCrossRef Fujimura A, Ebihara A. Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK506). Life Sci 1994; 55: 485–90PubMedCrossRef
74.
go back to reference Uchida H, Kobayashi E, Ogino Y, et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. Transplant Proc 1999; 31: 2751–3PubMedCrossRef Uchida H, Kobayashi E, Ogino Y, et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. Transplant Proc 1999; 31: 2751–3PubMedCrossRef
75.
go back to reference Yamauchi A, Oishi R, Kataoka Y, et al. Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats. Cell Mol Neurobiol 2004; 24: 695–704PubMedCrossRef Yamauchi A, Oishi R, Kataoka Y, et al. Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats. Cell Mol Neurobiol 2004; 24: 695–704PubMedCrossRef
76.
go back to reference Palm S, Postier E, Hinrichsen H, et al. Twenty-four hour analysis of lymphocyte subpopulations and cytokines in healthy subjects. Chronobiol Int 1996; 13: 423–34PubMedCrossRef Palm S, Postier E, Hinrichsen H, et al. Twenty-four hour analysis of lymphocyte subpopulations and cytokines in healthy subjects. Chronobiol Int 1996; 13: 423–34PubMedCrossRef
77.
go back to reference Bertouch JV, Roberts-Thomson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. BMJ 1983; 286: 1171–2PubMedCrossRef Bertouch JV, Roberts-Thomson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. BMJ 1983; 286: 1171–2PubMedCrossRef
78.
go back to reference Oellerich M, Armstrong VW, Schutz E, et al. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on Cyclosporin and Tacrolimus. Clin Biochem 1998; 31: 309–16PubMedCrossRef Oellerich M, Armstrong VW, Schutz E, et al. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on Cyclosporin and Tacrolimus. Clin Biochem 1998; 31: 309–16PubMedCrossRef
79.
80.
go back to reference Fiorina P, Lattuada G, Slvestrini C, et al. Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand J Immunol 1999; 50: 228–31PubMedCrossRef Fiorina P, Lattuada G, Slvestrini C, et al. Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand J Immunol 1999; 50: 228–31PubMedCrossRef
81.
go back to reference Jung FJ, Yang L, Häer L, et al. Melatonin in vivo prolongs cardiac allograft survival in rats. J Pineal Res 2004; 37: 36–41PubMedCrossRef Jung FJ, Yang L, Häer L, et al. Melatonin in vivo prolongs cardiac allograft survival in rats. J Pineal Res 2004; 37: 36–41PubMedCrossRef
82.
go back to reference Stefanovic V, Ivic M, Mitic M, et al. Diurnal urinary excretion of Cortisol and aldosterone in kidney graft recipients. Pathol Biol 1995; 43: 766–71PubMed Stefanovic V, Ivic M, Mitic M, et al. Diurnal urinary excretion of Cortisol and aldosterone in kidney graft recipients. Pathol Biol 1995; 43: 766–71PubMed
83.
go back to reference Cugini P, Lucia P, Scibilia G, et al. Twenty-four-hour pattern of atrial natriuretic peptide in heart transplantation: evidence for lack of circadian rhythm. Temporal inter-relathionships with plasma rennin activity, aldosterone and Cortisol. Int J Cardiol 1993; 42: 7–14PubMedCrossRef Cugini P, Lucia P, Scibilia G, et al. Twenty-four-hour pattern of atrial natriuretic peptide in heart transplantation: evidence for lack of circadian rhythm. Temporal inter-relathionships with plasma rennin activity, aldosterone and Cortisol. Int J Cardiol 1993; 42: 7–14PubMedCrossRef
84.
go back to reference Armbruster H, Vetter W, Uhlschmid G, et al. Circadian rhythm of plasma renin activity and plasma aldosterone in normal man and in renal allograft recipients. Proc Eur Dial Transplant Assoc 1975; 11: 268–76PubMed Armbruster H, Vetter W, Uhlschmid G, et al. Circadian rhythm of plasma renin activity and plasma aldosterone in normal man and in renal allograft recipients. Proc Eur Dial Transplant Assoc 1975; 11: 268–76PubMed
85.
go back to reference Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859–65PubMedCrossRef Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003; 43: 859–65PubMedCrossRef
86.
go back to reference Fujimura A, Ebihara A. Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). Life Sci 1994; 55: 485–90PubMedCrossRef Fujimura A, Ebihara A. Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). Life Sci 1994; 55: 485–90PubMedCrossRef
Metadata
Title
Chronopharmacokinetics of Ciclosporin and Tacrolimus
Authors
Prof. Massimo Baraldo
Mario Furlanut
Publication date
01-08-2006
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645080-00002

Other articles of this Issue 8/2006

Clinical Pharmacokinetics 8/2006 Go to the issue